Abstract
Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporating the novel oral anticoagulants (NOACs) into clinical management guidelines. Current guidelines recommend (a) administration of the antiplatelet agent aspirin in the acute management of ischemic stroke, (b) antiplatelet therapy - aspirin, clopidogrel, dypiridamole - in the secondary prevention of noncardioembolic (large artery atherosclerosis) ischemic stroke, and (c) anticoagulants - warfarin and the NOACs - in the secondary prevention of cardioembolic (atrial fibrillation related) ischemic stroke. In phase III clinical trials of the NOACs, dabigatran 150mg BID and apixaban 5mg BID were superior to warfarin in the prevention of stroke/systemic embolism while rivaroxaban 20mg QD demonstrated noninferiority. Both dabigatran and rivaroxaban had similar rates of major bleeding as warfarin but apixaban showed significantly reduced incidence of this complication. As application of novel anticoagulant agents increases, with concomitant study in a variety of clinical settings; their promise in reducing the incidence of stroke, as well as that of therapeutic complications related to warfarin, should be further elaborated.
Keywords: Stroke, anticoagulants, platelet aggregation inhibitors, atrial fibrillation, atherosclerosis, aspirin, warfarin, antithrombins.
Current Pharmaceutical Design
Title:Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke
Volume: 23 Issue: 9
Author(s): Shreya Shrestha, Shannon Coy and Kimon Bekelis*
Affiliation:
- Section of Neurosurgery, Dartmouth Hitchcock Medical Center, Lebanon, NH,United States
Keywords: Stroke, anticoagulants, platelet aggregation inhibitors, atrial fibrillation, atherosclerosis, aspirin, warfarin, antithrombins.
Abstract: Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporating the novel oral anticoagulants (NOACs) into clinical management guidelines. Current guidelines recommend (a) administration of the antiplatelet agent aspirin in the acute management of ischemic stroke, (b) antiplatelet therapy - aspirin, clopidogrel, dypiridamole - in the secondary prevention of noncardioembolic (large artery atherosclerosis) ischemic stroke, and (c) anticoagulants - warfarin and the NOACs - in the secondary prevention of cardioembolic (atrial fibrillation related) ischemic stroke. In phase III clinical trials of the NOACs, dabigatran 150mg BID and apixaban 5mg BID were superior to warfarin in the prevention of stroke/systemic embolism while rivaroxaban 20mg QD demonstrated noninferiority. Both dabigatran and rivaroxaban had similar rates of major bleeding as warfarin but apixaban showed significantly reduced incidence of this complication. As application of novel anticoagulant agents increases, with concomitant study in a variety of clinical settings; their promise in reducing the incidence of stroke, as well as that of therapeutic complications related to warfarin, should be further elaborated.
Export Options
About this article
Cite this article as:
Shrestha Shreya, Coy Shannon and Bekelis Kimon *, Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161221145614
DOI https://dx.doi.org/10.2174/1381612822666161221145614 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical and Molecular Perspectives of Monogenic Hypertension
Current Hypertension Reviews Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews Neuropeptide Conversion to Bioactive Fragments - An Important Pathway in Neuromodulation
Current Protein & Peptide Science Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Insulin Resistance and Postprandial Hyperglycemia the Bad Companions in Natural History of Diabetes: Effects on Health of Vascular Tree
Current Diabetes Reviews Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide
Recent Patents on Drug Delivery & Formulation The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Beyond Mitochondria, What Would be the Energy Source of the Cell?
Central Nervous System Agents in Medicinal Chemistry Cellular Actions of Nesfatin-1 on Hypothalamic and Medullary Neurons
Current Pharmaceutical Design Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Recent Patents on Microbial Proteases for the Dairy Industry
Recent Advances in DNA & Gene Sequences (Discontinued) The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Honey, Health and Longevity
Current Aging Science Alerting Reaction in Office Blood Pressure and Target Organ Damage: An Innocent Phenomenon?
Current Hypertension Reviews An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment
Current Medicinal Chemistry